Accessibility Menu
Lexicon Pharmaceuticals logo

Lexicon Pharmaceuticals

(NASDAQ) LXRX

Current Price$2.37
Market Cap$1.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)-98%
5 Year-36%
1 Year+77%
1 Month+17%
Lexicon Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 2.392026-07-17
Lexicon Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+7.66%USD 2.222026-07-10
1 month+17.16%USD 2.042026-06-17
3 month+27.81%USD 1.872026-04-17
Year to date+107.83%USD 1.152025-12-31
1 year+77.04%USD 1.352025-07-17
3 year+7.17%USD 2.232023-07-18
5 year-35.58%USD 3.712021-07-16
Since inception-98.18%USD 131.252000-04-07

Lexicon Pharmaceuticals Financials at a Glance

Market Cap

$1.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$69.64M

Net Income (TTM)

-$26.09M

EPS (TTM)

-$0.07

P/E Ratio

-33.43

Dividend

$0.00

Beta (Volatility)

1.59 (High)

Price

$2.37

Volume

2,431,579

Open

$2.22

Previous Close

$2.39

Daily Range

$2.19 - $2.40

52-Week Range

$1.00 - $2.68

Estimated Earnings Date

Aug 5, 2026

LXRX News

TMF-Bull-Statue-Purple-StockVStock.png

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?

Brendan CoffeyJun 11, 2026
Foolcom-Featured.png

Lexicon (LXRX) Q2 Revenue Soars 1,706%

Motley Fool Markets TeamAug 6, 2025
pharmacy pharmacist drug medicine prescription (2)

Why Shares of Lexicon Pharmaceuticals Are Up Tuesday

James HalleyOct 10, 2023
red arrow

Why Lexicon Pharmaceuticals Stock Crashed This Week

George Budwell, PhDJun 2, 2023
two investors look at figures

Wall Street's Counting on an FDA Nod for This Growth Stock to Nearly Double, but Should You?

Alex CarchidiMay 11, 2023
scientist researcher microscope lab

Should You Buy This Growth Stock Right Now Before It Potentially Doubles?

Alex CarchidiApr 22, 2023
Two people seated at a lab desk featuring a PC screen and microscope

Why Lexicon Pharmaceuticals Was Plunging on Monday

Eric VolkmanFeb 28, 2022
GettyImages-1209002984

Should You Buy Lexicon Pharmaceuticals Stock?

Alex CarchidiFeb 6, 2021
Page 1

LXRX: Motley Fool Moneyball Superscore

55

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lexicon Pharmaceuticals

Lexicon creates medicines that help people living with serious heart and metabolic conditions. Their main product helps patients manage heart failure and diabetes complications. The company also builds new treatments for chronic nerve pain and obesity.

What Lexicon is Building

  • INPEFA: Oral tablet used to reduce the risk of heart failure and cardiovascular death in adults.
  • Sotagliflozin: Drug candidate in final-stage testing for hypertrophic cardiomyopathy, which is a thickening of the heart muscle.
  • ZYNQUISTA: Potential treatment for type 1 diabetes currently undergoing regulatory review with the Food and Drug Administration.
  • Pilavapadin: Medicine in mid-stage testing for neuropathic pain, which is chronic pain caused by nerve damage.
  • LX9851: Experimental drug for obesity and metabolic issues being developed through a partnership with another company.

Deals with Big Pharma

  • Granted Novo Nordisk an exclusive worldwide license in March 2025 to develop and sell obesity drug candidate LX9851.
  • Partnered with Viatris Inc. in October 2024 to sell heart failure medication in Canada, Australia, and other territories.
  • Received a $45 million upfront payment and $10 million milestone from Novo Nordisk for the LX9851 agreement.
  • Advanced third-party collaboration talks to support the future development and sale of the pain treatment pilavapadin.

Science Behind the Pills

Lexicon uses a special method called gene knockout technology to find drug targets by studying genes in mice. This scientific approach helps the company understand how human proteins could be used to treat specific diseases.

The Latest Financial Facts

  • Revenue was $5.5 million in Q4 2025, down 79.3% from $26.6 million in Q4 2024.
  • Gross profit reached $5.2 million in Q4 2025, up 733.2% from $621,000 in Q4 2024.
  • Net losses narrowed to $15.5 million in Q4 2025, an improvement of 54% from the previous year.
  • Operating cash flow improved to negative $17.2 million in Q4 2025, up 19.8% year-over-year.
  • Free cash flow hit negative $17.2 million in Q4 2025, narrowing by 21.5% from Q4 2024.

Evolution of a Biotech Firm

Lexicon is evolving from a research-focused business into a commercial pharmaceutical company. Its growth relies on expanding its heart failure treatments and securing new drug approvals.

AI Generated • May 4, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

81

CEO

Michael Exton, PhD

Website

www.lexpharma.com

Headquarters

The Woodlands, TX 77381, US

LXRX Financials

Key Financial Metrics (TTM)

Gross Margin

99.07%

Operating Margin

-34.79%

Net Income Margin

-37.46%

Return on Equity

-18.64%

Return on Capital

-28.81%

Return on Assets

-9.71%

Earnings Yield

-2.99%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

444.20M

Volume

2.43M

Avg. Volume

3.27M

Financials (TTM)

Gross Profit

$69.00M

Operating Income

-$24.23M

EBITDA

-$17.44M

Operating Cash Flow

-$38.80M

Capital Expenditure

$0.00

Free Cash Flow

-$38.80M

Cash & ST Invst.

$170.66M

Total Debt

$57.71M

Lexicon Pharmaceuticals Performance Analysis

Lexicon Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 139,000-53.4%
20232023-12-31USD 1,204,000766.2%
20242024-12-31USD 31,081,0002481.5%
20252025-12-31USD 49,803,00060.2%
Lexicon Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-302187.3%
Q32025-09-30-50.9%
Q42025-12-31-61.3%
Q12026-03-31284.2%
Lexicon Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.622.1%
20232023-12-31USD -0.8030.2%
20242024-12-31USD -0.63-21.8%
20252025-12-31USD -0.14-77.9%
Lexicon Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30112.7%
Q32025-09-30-494.4%
Q42025-12-31-21.7%
Q12026-03-3193.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$21.10M

+1572.1%

Gross Profit

$20.99M

+1604.1%

Gross Margin

99.49%

N/A

Market Cap

$1.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$13.11M

N/A

Employees

81

N/A

Net Income

-$1.04M

+95.9%

EBITDA

$657.00K

+102.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$170.66M

-12.4%

Total Debt

$57.71M

-45.7%

Accounts Receivable

$11.78M

-75.2%

Inventory

$276.00K

+37.3%

Long Term Debt

$56.07M

-11.2%

Short Term Debt

$1.64M

-96.2%

Return on Assets

-9.71%

N/A

Return on Invested Capital

-9.36%

N/A

Free Cash Flow

-$14.73M

+66.4%

Operating Cash Flow

-$14.73M

+66.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RAPTRAPT Therapeutics, Inc.
$58.01+0.00%
OMEROmeros Corporation
$9.69+5.10%
FDMT4D Molecular Therapeutics, Inc.
$10.99+1.38%
OCGNOcugen, Inc.
$1.36-0.73%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$95.04-0.02%
PATHUiPath
$12.15+0.01%
JOBYJoby Aviation
$7.23-0.01%
TAT&T
$21.81-0.01%

Questions About LXRX

What is the current price of Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals is trading at $2.39 per share.

What is the 52-week range for Lexicon Pharmaceuticals?

Over the past 52 weeks, Lexicon Pharmaceuticals has traded between $1.00 and $2.68.

How much debt does Lexicon Pharmaceuticals have?

As of the most recent reporting period, Lexicon Pharmaceuticals reported total debt of $57.71M.

How much cash does Lexicon Pharmaceuticals have on hand?

Lexicon Pharmaceuticals reported $38.09M in cash and cash equivalents in its most recent financial results.

What is Lexicon Pharmaceuticals’s dividend yield?

Lexicon Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services